Results 211 to 220 of about 6,312,461 (358)

Identification of patients with potential palliative care needs: A systematic review of screening tools in primary care [PDF]

open access: hybrid, 2020
Yousuf ElMokhallalati   +6 more
openalex   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

TRATAMIENTO CON CÉLULAS MADRES PARA EL INFARTO DE MIOCARDIO AGUDO

open access: yesRevista Médica Clínica Las Condes, 2018
Sheila A. Fisher   +4 more
doaj   +1 more source

Bisphenol A and human fertility: a systematic review. [PDF]

open access: yesJBRA Assist Reprod
Isa CPM   +9 more
europepmc   +1 more source

Medications That Cause Dry Mouth As an Adverse Effect in Older People: A Systematic Review and Metaanalysis [PDF]

open access: bronze, 2017
Edwin C.K. Tan   +4 more
openalex   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

open access: yesMolecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed   +10 more
wiley   +1 more source

Exophiala infection: A systematic review. [PDF]

open access: yesMedicine (Baltimore)
Xue S, Wang J, Wang H, Jiang Y, Long J.
europepmc   +1 more source

Oral Is the New IV. Challenging Decades of Blood and Bone Infection Dogma: A Systematic Review

open access: green, 2021
Noah Wald‐Dickler   +6 more
openalex   +2 more sources

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

open access: yesMolecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto   +13 more
wiley   +1 more source

Anti-IgLON5 Disease: A Systematic Review and Meta-Analysis. [PDF]

open access: yesEur J Neurol
Grossauer A   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy